Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy (PACE-nHCM)

This will be a two-arm investigator-initiated randomized controlled study of patients with nHCM and LV ejection fraction ≥50% and NYHA II-III symptoms, normal intrinsic conduction system and pre-existing suitable dual-chamber implantable cardioverter defibrillators (ICD) systems. Patients will be randomly assigned to either personalized accelerated pacing (using the myPACE+ algorithm with mono-fractional exponent) or usual care groups. At baseline and after 3 months of pacing all patients will undergo a CPET, echocardiogram, blood work for NT-proBNP levels and complete the KCCQ-OSS and HCMSQ, questionnaires.

The investigator team hypothesizes that personalized accelerated pacing will be safe and improve symptoms and heart-failure related quality of life, physical activity, pVO2, biomarkers (i.e. NT-proBNP), diastolic parameters and cardiac structure.

Study Overview

• Status: Terminated
• Conditions: Hypertrophic Cardiomyopathy; Non-obstructive Hypertrophic Cardiomyopathy
• Intervention / Treatment: Other: myPACE+ algorithm

Detailed Description

This will be a two-arm investigator-initiated randomized controlled study of patients with nHCM and LV ejection fraction≥50% and NYHA II-III symptoms, normal intrinsic conduction system and pre-existing suitable dual-chamber implantable cardioverter defibrillators (ICD) systems. Patients will be randomly assigned to either personalized accelerated pacing (using the myPACE+ algorithm with mono-fractional exponent) or usual care groups. At baseline and after 3 months of pacing all patients will undergo a CPET, echocardiogram, blood work for NT-proBNP levels and complete the KCCQ-OSS and HCMSQ, questionnaires.

The investigator team hypothesizes that personalized accelerated pacing will be safe and improve symptoms and heart-failure related quality of life, physical activity, pVO2, biomarkers (i.e. NT-proBNP), diastolic parameters and cardiac structure. An interim data safety analysis will be conducted.

• Study Type: Interventional
• Enrollment (Actual): 1
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • New York
    • The Bronx, New York, United States, 10467
      • Montefiore Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Non obstructive HCM: Left Ventricular Outflow Tract (LVOT) gradient <30mmHg at rest and with provocation
• Left ventricular ejection fraction (LVEF) ≥50%
• New York Heart Association (NYHA II-III) symptoms
• Normal intrinsic conduction system
• Suitable dual-chamber implantable cardioverter defibrillators (ICD) system

Exclusion Criteria:

• Pregnancy
• LVEF <50%
• LVOT gradient > 30mmHg at rest or with provocation
• Prolonged PR > 250ms
• Baseline RV-pacing burden of > 1% more than moderate valvular stenosis or regurgitation
• Aortic valve replacement in the past one year
• Significant primary pulmonary disease on home oxygen
• Uncontrolled hypertension as defined by BP >160/100 mmHg on two measurements ≥15 minutes apart

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: myPACE+; Participants will be programmed to a personalized lower rate setting based on the myPACE+ resting heart rate algorithm will be conducted using the myPACE+ algorithm	Other: myPACE+ algorithm; myPACE+ algorithm with mono-fractional exponent
No Intervention: Usual Care; Standard of care. Participants will retain a standard pacing lower rate setting of 60 beats per minute (bpm).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Health-Related Quality of Life (HRQoL) status	Change in HRQoL from prior to randomization to the time of 3-month follow-up will be assessed based on patient responses to the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12). The KCCQ-12 is a validated health status measure for patients with heart failure. An overall summary score (OSS) is tabulated based on responses ranging from 0-100, with 0 denoting the worst and 100 the best possible HRQoL status. Change from baseline scores will be summarized by study arm using basic descriptive statistics. A logistic mixed-effect model will be employed to calculate the odds ratio for a ≥ 5 point or more improvement of the KCCQ-OSS, which is considered clinically meaningful.	Baseline to 3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels	Change in NT-proBNP concentration from baseline to 3-month follow-up will be summarized by study arm using basic descriptive statistics and subsequently compared between groups. Samples will be obtained by venipuncture and submitted to a local laboratory for analysis. While normal NT-proBNP levels vary by age, the normal threshold for those under 50 years of age is 450 pg/mL, while it is 900 pg/mL for those greater than 50 years of age. Higher than normal NT-proBNP levels may be indicative of heart failure. As part of an exploratory analysis for this trial a >29% decrease in NT-proBNP concentration from baseline will be considered a "clinically meaningful threshold"	Baseline to 3 months
Change in Peak Oxygen (pVO2) Uptake and predicted pVO2	Change in pVO2 and predicted pVO2 from baseline to 3-month follow-up will be measured by cardiopulmonary exercise testing (CPET). CPET is a functional assessment that helps to detect disorders affecting the system involved in oxygen transport and utilization through the analysis of gas exchange during exercise. Change in pVO2 uptake from baseline will be summarized by study arm using basic descriptive statistics and analyzed by win ratios. An increase in pVO2 >1.5mL/kg/min from baseline will be considered a "clinically meaningful threshold" as part of an exploratory analysis for this trial.	Baseline to 3 months
Change in pacemaker-detected atrial arrhythmia burden	Change in pacemaker-detected atrial arrhythmia burden from baseline to 3-month follow-up will be assessed by interrogation of the pacemaker. Pacemaker-detected data will be continuously collected and stored by the pacemaker. Atrial arrhythmia burden is quantified as the percentage of time per day the patient is in atrial fibrillation (AF). Change in percentage over time will be summarized by study arm using basic descriptive statistics and analyzed by win ratios. Pacemaker-detected arrhythmia burden is associated with more adverse cardiac outcomes including increased risk of stroke or thromboembolism.	Baseline to 3 months
Change in pacemaker-detected patient activity level	Change in pacemaker-detected patient activity levels from baseline to 3-month follow-up will be assessed using the pacemaker's built-in accelerometer. This accelerometer can measure a patient's physical activity levels by detecting the frequency and amplitude of a patient's motion. The device measures the number of hours/minutes the patient is active, based on a threshold for the number and magnitude of accelerometer signal deflections. Change in pacemaker-detected patient activity levels from baseline will be summarized by study arm using basic descriptive statistics and analyzed by win ratios. As part of an exploratory analysis for this trial an increase in pacemaker detected daily activity >0.5 hour/day from baseline will be considered a "clinically meaningful threshold".	Baseline to 3 months
Change in echocardiographic parameters: Left Atrial (LA) Strain	Change in LA strain from baseline to 3-month follow-up will be assessed using TTE. Strain is a measure of deformation of the myocardium during the cardiac cycle in multiple directions; lengthening, shortening and thickening and is expressed as a fractional length change, where shortening is a negative value and lengthening a positive value. The difference between length at the reference point (end-diastole) and the current length (end-systole) will be calculated in accordance with American Society of Echocardiography (ASE) January 2015 guidelines related to strains. This is then divided by original reference length and then expressed as a percentage for the given timepoint. Change in this percentage from baseline will be summarized by study arm using basic descriptive statistics and analyzed by win ratios. LA strain is an earlier marker of underlying cardiovascular pathology than many conventional echocardiographic parameters given the relatively thinner walls of the atria.	Baseline to 3 months
Change in echocardiographic parameters: Left Ventricular (LV) Strain	Change in LV strain from baseline to 3-month follow-up will be assessed using transthoracic echocardiogram (TTE). Strain is a measure of deformation of the myocardium during the cardiac cycle in multiple directions; lengthening, shortening and thickening and is expressed as a fractional length change, where shortening is a negative value and lengthening a positive value. The difference between length at the reference point (end-diastole) and the current length (end-systole) will be calculated in accordance with (ASE) January 2015 guidelines related to strain. This is then divided by original reference length and then expressed as a percentage for the given timepoint. Change in this percentage from baseline will be summarized by study arm using basic descriptive statistics and analyzed by win ratios. LV Strain can be used for the early detection of left ventricular dysfunction by detecting subtle changes in deformation of heart muscle, which can lead to earlier diagnosis/prognosis.	Baseline to 3 months
Change in echocardiographic E/e' ratio	Change in echocardiographic E/e' ratio from baseline to 3-month follow-up will be assessed using transthoracic echocardiogram (TTE). E/e' ratio is a measure of diastolic function that is calculated by dividing the peak E wave velocity (early filling velocity, or E) by the peak e' wave velocity (or the early relaxation velocity, e') and will be calculated in accordance with (ASE) January 2015 guidelines. Elevated E/e' ratios are a key indicator of left ventricular end-diastolic pressure and, as such, are often used to assess the severity of diastolic dysfunction. Change in E/e' ratios will be summarized by study arm using basic descriptive statistics and analyzed by win ratios.	Baseline to 3 months
Change in Left Ventricular Myocardial Thickness (LVMT)	Change LVMT from baseline to 3-month follow-up will be evaluated using motion-mode echocardiography in accordance with (ASE) January 2015 guidelines. This one-dimensional view allows for digitized, linear measurements of LV thickness in the parasternal long-axis view. Increased LV myocardial wall thickness can lead to Left ventricular hypertrophy (LVH), making it more difficult for the heart to pump blood and increase the risk of unfavorable cardiovascular outcomes. Change in LV myocardial thickness will be summarized by study arm using basic descriptive statistics and analyzed by win ratios.	Baseline to 3 months
Change in Left Atrial (LA) chamber size	Change in LA chamber size from baseline to 3-month follow-up will be evaluated using transthoracic echocardiogram (TTE) in accordance with (ASE) January 2015 guidelines. An enlarged left atrium, known as Left Atrial Enlargement (LAE), is a result of increased left atrial pressure over a prolonged period and can be a predictor of clinically significant cardiovascular diseases and heart failure. Change in LA chamber size from baseline will be summarized by study arm using basic descriptive statistics and analyzed by win ratios.	Baseline to 3 months
Change in Left Ventricular (LV) chamber size	Change in LV chamber size from baseline to 3-month follow-up will be evaluated using transthoracic echocardiogram (TTE) in accordance with (ASE) January 2015 guidelines. An increased left ventricular chamber size is caused by elevated blood pressure over a prolonged period and can lead to Left Ventricular Hypertrophy (LVH) complications of which can lead to heart failure or sudden cardiac death. Change in LV chamber size from baseline will be summarized by study arm using basic descriptive statistics and analyzed by win ratios.	Baseline to 3 months

Collaborators and Investigators

• Sponsor: Montefiore Medical Center
• Collaborators: Medtronic
• Investigators: Principal Investigator: Luigi Di Biase, MD, Montefiore Medical Center

Publications and helpful links

General Publications

• Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022 May 3;79(17):1757-1780. doi: 10.1016/j.jacc.2021.12.011. Epub 2022 Apr 1.
• Infeld M, Wahlberg K, Cicero J, Plante TB, Meagher S, Novelli A, Habel N, Krishnan AM, Silverman DN, LeWinter MM, Lustgarten DL, Meyer M. Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction: The myPACE Randomized Clinical Trial. JAMA Cardiol. 2023 Mar 1;8(3):213-221. doi: 10.1001/jamacardio.2022.5320.
• Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020 Dec 22;76(25):3022-3055. doi: 10.1016/j.jacc.2020.08.044. Epub 2020 Nov 20.
• Weissler-Snir A, Rakowski H, Meyer M. Beta-blockers in non-obstructive hypertrophic cardiomyopathy: time to ease the heart rate restriction? Eur Heart J. 2023 Oct 1;44(37):3655-3657. doi: 10.1093/eurheartj/ehad518. No abstract available.

Study record dates

Study Major Dates

• Study Start (Actual): October 2, 2025
• Primary Completion (Actual): October 23, 2025
• Study Completion (Actual): October 23, 2025

Study Registration Dates

• First Submitted: January 9, 2025
• First Submitted That Met QC Criteria: January 9, 2025
• First Posted (Actual): January 15, 2025

Study Record Updates

• Last Update Posted (Actual): February 11, 2026
• Last Update Submitted That Met QC Criteria: February 8, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Cardiomyopathy; Heart Failure with preserved Ejection Fraction (HFpEF); Personalized Accelerated Pacing
• Additional Relevant MeSH Terms: Aortic Valve Disease; Cardiovascular Diseases; Heart Diseases; Heart Valve Diseases; Aortic Stenosis, Subvalvular; Aortic Valve Stenosis; Cardiomyopathies; Cardiomyopathy, Hypertrophic
• Other Study ID Numbers: 2024-16244

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No